Pharma — India Patent Cases
967 decisions indexed
Page 8 of 33 · 967 total
Modi-Mundipharma Pvt. Ltd. & Anr. v.Win Health Pharma Through Its Proprietor Mr. Sanjay Seth & Anr.
The Delhi High Court allowed the plaintiffs to challenge the validity of the defendant's registered trademarks, 'WIN HEALTH PHARMA,' under Section 124 of the Trademarks Act. The core dispute revolves around prior use rights, as the plaintiff claims established goodwill with marks like 'WIN-HEALTHCARE' since 2005, while the defendant holds registrations for similar names. Given that both parties presented substantial arguments regarding priority and similarity, the court found prima facie merit in the plaintiffs' plea of invalidity.
Astrazeneca Ab & Anr. v.Westcoast Pharmaceutical Works Limited
Astrazeneca filed suit against Westcoast Pharmaceutical Works Limited alleging infringement of its patent (IN 297581) covering the cancer drug Osimertinib. The plaintiffs sought permanent injunctions and damages, asserting that the defendant's offer to contractually manufacture and sell the patented compound constituted infringement. Despite initial defenses by the defendant regarding regulatory approval issues, the court found that due to the defendant's failure to file a written statement within the statutory period, the suit was decreed in favor of AstraZeneca, granting them relief and substantial costs.
Opella Healthcare Group v.Vaibhav Vohra & Anr.
The Delhi High Court ruled in favor of Opella Healthcare Group, ordering the cancellation of a competing trademark and copyright held by Vaibhav Vohra & Anr. The court found that the respondent's mark 'PHENSERYL' was phonetically and visually deceptively similar to the petitioner’s long-established mark 'PHENSEDYL,' leading to potential consumer confusion in the pharmaceutical sector. Furthermore, the court cancelled the associated copyright registration due to substantial imitation of the petitioner's original artistic packaging.
F- Hoffmann -La Roche Ag & Anr. v.Zydus Lifesciences Limited
The plaintiffs filed an application seeking permanent injunctions and recall orders against the defendant regarding the sale of 'Sigrima', a biosimilar of Pertuzumab, infringing patents IN 268632 and IN 464646. The court dismissed the application, finding that the plaintiffs failed to establish a prima facie case or demonstrate irreparable loss.
Embio Limited v.Malladi Drugs & Pharmaceuticals Ltd.
Embio Limited filed a petition seeking revocation of Patent No. 249376 granted to Malladi Drugs & Pharmaceuticals Ltd., alleging that the patent lacked novelty and inventive step. The court examined the arguments regarding prior art and technical advancement but found no illegality or perversity in the grant.
Master Arnesh Shaw Through His Next Friend And ... v.Union Of India & Anr.
The petition addressed the cumbersome and long-drawn process for procuring specialized medicines for DMD patients on a patient-by-patient basis. The court directed M/s. Sarepta to document a bulk procurement process and provide details of all its relevant Indian patents and patent applications.
Master Arnesh Shaw v.Union Of India & Anr.
The court heard matters concerning the procurement process for medicines used for DMD patients, noting that the current patient-by-patient system is cumbersome and unrealistic. The court directed M/s. Sarepta Therapeutics to present a general bulk procurement process and disclose its relevant patent portfolio in India.
Lakshay Agarwal v.Union Of India & Anr.
The petitioner raised concerns regarding the extremely cumbersome and long-drawn process for procuring specialized medicines on a patient-to-patient basis. The court directed M/s. Sarepta Therapeutics to place on record the general bulk procurement process and provide details of all its granted patents and patent applications filed in India concerning DMD medicines.
Pfizer Inc v.Teena Biolabs Private Limited
Pfizer Inc filed an Original Petition seeking the appointment of a Local Commissioner and the establishment of a Confidentiality Club. The petition aimed to facilitate the collection of confidential documents and testimony from Teena Biolabs Private Limited in India, which are relevant to ongoing patent infringement litigation (US Patent No. 9,770,441) before the US District Court for the District of Delaware.
Bry-Air (Asia) Pvt. Ltd. v.Union Of India, Through Its Secretary, Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry & Anr.
Bry-Air (Asia) Pvt. Ltd. challenged the status update issued by the Union of India, which deemed its patent application withdrawn under Section 11B(4) due to non-filing of a request for examination. The petitioner argued that this failure was solely attributable to the negligence of their erstwhile Patent Agent and not due to any fault or lack of intent on their part. Citing previous judgments where courts extended time in such circumstances, the Delhi High Court allowed the petition. Consequently, the court quashed the deemed withdrawal status and directed the Indian Patent Office to restore the application and allow the petitioner a chance to proceed with examination.
Bdr Pharmaceuticals International Pvt Ltd v.Kudos Pharmaceuticals Limited & Anr.
The suit concerned infringement of Patent IN 2287201 for Olaparib (LYNPARZA). The Plaintiff sought a temporary injunction and deposit of revenues. Given the patent was nearing its expiration, the Court issued directions requiring the Defendant to disclose earnings and earmark 20% of net sales value in a No Lien account.
Mankind Pharma Limited v.Sanshiv Health Tech Private Limited & Anr.
The Delhi High Court issued a significant interim order in the pharmaceutical infringement suit filed by Mankind Pharma Limited. The court exempted the plaintiff from mandatory pre-litigation mediation, recognizing the urgency of the matter. Crucially, the court allowed an application seeking an ex-parte ad-interim injunction and appointed Local Commissioners to conduct search and seizure at the defendants' premises. This order provides a robust mechanism for the plaintiff to secure evidence related to alleged infringement.
Panacea Biotec Limited v.Sanofi Healthcare India Private Limited
Panacea Biotec Limited filed a patent infringement suit against Sanofi Healthcare India Private Limited concerning the product Shan6, which allegedly infringes IN 351. The parties reached an amicable resolution and settled the dispute before the Delhi High Court.
Axcess Limited v.Controller Of Patents And Designs
Axcess Limited appealed the Controller's refusal of its Indian Patent Application (No. 2427/DELNP/2011), which covered bile acids and biguanides as protease inhibitors for gut peptides. The Controller had rejected the application under Section 59(1) of the Patent Act, arguing that the amendments exceeded the original scope. However, the Delhi High Court found that a detailed examination of the complete specification supported the amended claims regarding composition as a product. Consequently, the court set aside the rejection and remanded the matter back to the Controller for fresh consideration.
INCYTE HOLDINGS CORPORATION v.GLENMARK PHARMACEUTICALS LIMITED
The plaintiffs sought a decree of permanent injunction against the defendants concerning Indian Patent No. 269841. The defendants submitted that they had not commercialized any product containing 'Ruxolitinib' and did not intend to do so in the future.
Enterabio Ltd. v.The Controller General of Patents & Designs, Mumbai & Anr.
Enterabio Ltd. appealed against the rejection of its patent application for an oral pharmaceutical composition containing insulin and a protease inhibitor. The High Court found that the Assistant Controller failed to provide adequate reasons for rejecting the claim and did not comply with procedural rules regarding amendments. Consequently, the court set aside the impugned order and remanded the matter back to the Controller.
Bristol-Myers Squibb Holdings Ireland v.Km Swarnalatha & Ors.
Bristol-Myers Squibb Holdings Ireland filed a suit seeking permanent injunction against infringement of Indian Patent No. IN 203937, which covers dasatinib. The court examined the connection between various defendants involved in manufacturing and marketing the drug. Ultimately, the court found that Defendant No. 7 had launched the impugned product under the brand name DASA SPL without appearing before the court. Consequently, the suit was decreed against the parties based on these findings.
Sun Pharma Laboratories Limited v.Jyotiben Hareshbhai Chovatiya and Ors.
The Plaintiff sought permission to add several associated entities (Defendants No. 4 to 6) as party defendants, alleging they were involved in dealing with goods bearing an impugned trade mark 'NEUROGABA'. The Court found that these parties were necessary and proper for the adjudication of the matter.
Astrazeneca Ab v.Everest Pharmaceuticals Limited
Astrazeneca filed a suit seeking permanent injunction against Everest Pharmaceuticals for infringing its patent IN 297581, which covers the compound Osimertinib. The court found that the plaintiffs made out a prima facie case and granted an ad interim ex-parte injunction restraining the defendants from manufacturing or selling the infringing product until further hearing.
Astrazeneca Ab v.Beacon Pharmaceuticals Plc
Astrazeneca filed a suit seeking permanent injunction against Beacon Pharmaceuticals and others for infringing its patent (IN 297581) covering the compound Osimertinib. The court, after considering the prima facie case, granted an ad interim ex-parte injunction restraining the defendants from selling or offering the patented compound in any form.
Natco Pharma Ltd. v.M/s. Schering Corporation
Natco Pharma Ltd filed an Original Petition (Patents) seeking the revocation of Indian Patent No.202128 against M/s. Schering Corporation and the Assistant Controller of Patents & Designs. The court observed that the term of the patent had expired on 06.10.2018, rendering the petition infructuous.
Sun Pharma Laboratories Ltd v.Resolute Healthcare & Ors.
The Delhi High Court granted an ex-parte ad-interim injunction in favor of Sun Pharma Laboratories Ltd against Resolute Healthcare & Ors. The court found that the defendant's mark, 'TRYGABA', is deceptively similar to the plaintiff's registered trademark, 'TRIGABANTIN'. Given that both products treat neuropathic pain and the similarity was intentional (truncation), the court restrained the defendants from manufacturing or selling the infringing product until further notice. The injunction allows the defendants a grace period of three months to exhaust their current stock.
M/s.Guangzhou Ocusun Ophthalmic Biotechnology Company Limited v.Joint Controller of Patents & Designs
The appeal challenged the rejection of a patent application concerning a crystal form of lanosterol prodrug compound. The appellant argued that the new form exhibited significant therapeutic efficacy, particularly in treating cataract symptoms, which was not adequately considered by the original examiner. The High Court set aside the rejection order and remanded the matter for reconsideration.
M/s.Guangzhou Ocusun Ophthalmic Biotechnology Company Limited v.Joint Controller of Patents & Designs
The appeal challenged the rejection of Patent Application No. 202147005676 for a crystal form of lanosterol prodrug compound. The appellant argued that the invention exhibited significant therapeutic efficacy, particularly in reducing cataract symptoms in neonatal rabbits. The High Court found that the impugned order failed to properly consider the experimental data demonstrating pharmacodynamic studies and set aside the rejection, remanding the matter for reconsideration.
Micro Labs Limited v.The Controller Of Patents & Anr.
Micro Labs Limited filed a petition seeking revocation of Indian Patent No. 247381, while Bristol-Myers Squibb Ireland Unlimited Company sought permanent injunction against Micro Labs for infringing the patent using 'Apixaban' and 'APIVAS'. The parties successfully negotiated a settlement agreement in mediation.
Astrazeneca Ab v.T Rao
The Delhi High Court framed multiple issues regarding the validity of three Indian Patents (IN 209907, IN 247984, IN 272674) held by Astrazeneca Ab. The court also addressed infringement claims related to the product TICAGRELOR and granted procedural directions for evidence recording.
Micro Labs Limited v.The Controller Of Patents & Anr.
Micro Labs Limited filed a petition seeking revocation of Indian Patent No. 247381, while Bristol-Myers Squibb Ireland Unlimited Company sought permanent injunction against Micro Labs for infringing the patent using 'Apixaban' and 'APIVAS'. The parties successfully negotiated a settlement agreement in mediation.
M/S Rspl Health Private Limited v.Mittal Industrial Corporation & Anr
The Delhi High Court addressed several applications in the trademark dispute between M/S Rspl Health Private Limited and Mittal Industrial Corporation & Anr. While procedural matters like exemption from certified copies were granted, the core petition seeking removal or rectification of the impugned trademark 'SAGAR SUPREME LABEL' was advanced. The court accepted notice and directed all parties to file their replies within specified timelines, setting the stage for a substantive hearing on the alleged deceptive similarity.
Chia Tai Tianqing Pharmaceutical Group Co Ltd v.Assistant Controller of Patents and Designs
This appeal was filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd against an order dated March 14, 2024, passed by the Assistant Controller of Patents and Designs. The original application for patent (No. 202117022431) was rejected based on objections under Section 2(1)(ja) and Section 3(d) of the Indian Patents Act, 1970.
INCYTE HOLDINGS CORPORATION v.DR REDDYS LABORATORIES LIMITED
The plaintiffs filed a suit seeking permanent injunction against the defendant for infringing copyright. The defendant raised defenses regarding service of documents and asserted that its activities are limited to permissible uses under Section 107A of the Patents Act, 1970.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.